Harmful drinking and alcohol dependence: advice from recent NICE guidelines

INTRODUCTION
Harmful drinking is defined as a pattern of alcohol consumption causing health problems directly related to alcohol. Alcohol dependence is characterised by craving, tolerance, a preoccupation with alcohol, and continued drinking in spite of harmful consequences. In England over 24% of the population consumes alcohol in a way that is potentially or actually harmful to their health or wellbeing and alcohol dependence affects 4% of people aged between 16 and 65 years. The National Institute of Health and Clinical Excellence has produced guidance on alcohol use disorders covering, diagnosis, assessment, and management of harmful drinking and alcohol dependence,1 and the diagnosis and management of alcohol-related physical complications2 It is consistent with the Department of Health’s report Models of Care for Alcohol Misusers.3 This set out four tiers of intervention; primary health care is a suitable setting for Tier one (identification of hazardous, harmful, and dependent drinkers; information on sensible drinking; simple brief interventions to reduce alcohol-related harm; and referral of those with alcohol dependence or harm for more intensive interventions) and Tier two (provision of open access facilities and outreach that provide: alcohol-specific advice, information, and support; extended brief interventions to help alcohol misusers reduce alcohol-related harm; and assessment and referral of those with more serious alcohol-related problems).

Assessment
Four levels of assessment are described. Level one is case identification/diagnosis; level two is withdrawal assessment; level three is triage assessment; and level four is comprehensive assessment. The assessment of risk should be part of any assessment. This includes risk to self (including unplanned withdrawal, suicidality, and neglect) and risk to others. The extent of any associated health and social problems and the need for assisted alcohol withdrawal should also be part of assessment.

1. Case identification
The objective of case identification is to identify people who need an intervention for harmful drinking or alcohol dependence, and to identify those who may need referral for comprehensive assessment as they have not responded to brief interventions in the past, need assisted alcohol withdrawal, or show signs of clinically significant alcohol-related impairment. Case identification should consider:

• establishing the probable presence of an alcohol-use disorder;
2. Withdrawal assessment

The assessment of the need for a medically managed withdrawal also uses the AUDIT score. A person who drinks more than 15 units of alcohol a day or scores ≥20 on AUDIT should be considered for an assisted withdrawal. Inpatient and residential assisted withdrawal should be considered if one or more of the following criteria are met:

- daily intake over 30 units of alcohol;
- have a score of more than 30 on the Severity of Alcohol Dependence Questionnaire (SADQ);
- have a history of epilepsy or experience of withdrawal-related seizures or delirium tremens during previous assisted withdrawal programmes;
- need concurrent withdrawal from alcohol and benzodiazepines; and
- regularly drink between 15 and 20 units of alcohol per day and have:
  - significant psychiatric or physical comorbidities (for example, chronic severe depression, psychosis, malnutrition, congestive cardiac failure, unstable angina, chronic liver disease); or
  - a significant learning disability or cognitive impairment.

People who are alcohol dependent should be advised not to suddenly reduce intake of alcohol to avoid withdrawal and referred to local alcohol support services. Community-based assisted withdrawal is appropriate for people with mild to moderate dependence. Programmes should consist of a drug regimen and psychosocial support including motivational interviewing. An average of two to four meetings between staff and the patient per week in the first week is suggested. Fixed dose regimens are recommended for community-based withdrawal programmes and symptom-triggered regimes reserved for an inpatient setting where appropriate monitoring is available. A fixed dose regimen involves starting treatment with a standard dose, not defined by the level of alcohol withdrawal and reducing the dose to zero over 7–10 days according to a standard protocol. The preferred medication for assisted withdrawal is a benzodiazepine (clorazepate or diazepam). Clomethiazole should not be used for assisted withdrawal in the community because of the risk of overdose and misuse. The initial dose of medication should be titrated to the severity of alcohol dependence and/or regular daily level of alcohol consumption. The guidance

---

**REFERENCES**


Onset: 6–8 hours  Generalised hyperactivity, tremor, sweating, nausea, retching, mood fluctuation, tachycardia, increased respirations, hypertension, and mild pyrexia
Subsides: 40–50 hours
Onset: 0–48 hours  Withdrawal seizures
Onset: 12 hours  Auditory and visual hallucinations may develop that are characteristically frightening
Duration: 5–6 days  Delirium tremens: coarse tremor, agitation, fever, tachycardia, mood fluctuation, tachycardia, increased respirations, profound confusion, delusions, and hallucinations

Provenance
Freely submitted; not externally peer reviewed.

Discuss this article
Contribute and read comments about this article on the Discussion Forum: http://www.rcgp.org.uk/bjgp-discuss

Table 1. Alcohol withdrawal symptoms and their timelines

<table>
<thead>
<tr>
<th>Timeline from last drink</th>
<th>Alcohol withdrawal symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset: 6–8 hours</td>
<td>Generalised hyperactivity, tremor, sweating, nausea, retching, mood fluctuation, tachycardia, increased respirations, hypertension, and mild pyrexia</td>
</tr>
<tr>
<td>Subsides: 40–50 hours</td>
<td>Withdrawal seizures</td>
</tr>
<tr>
<td>Onset: 0–48 hours</td>
<td>Withdrawal seizures</td>
</tr>
<tr>
<td>Onset: 12 hours</td>
<td>Auditory and visual hallucinations may develop that are characteristically frightening</td>
</tr>
<tr>
<td>Duration: 5–6 days</td>
<td>Delirium tremens: coarse tremor, agitation, fever, tachycardia, mood fluctuation, tachycardia, increased respirations, profound confusion, delusions, and hallucinations</td>
</tr>
</tbody>
</table>

Interventions: maintenance of abstinence
For harmful drinkers and people with mild alcohol dependence, a psychological intervention focused specifically on alcohol-related cognitions, behaviour problems, and social networks is recommended. Acamprosate or oral naltrexone can be added for people who have not responded to psychological interventions alone, or who have specifically requested a pharmacological intervention.

For people with moderate and severe alcohol dependence acamprosate or oral naltrexone can be added following successful withdrawal. Disulfiram may be used when acamprosate and oral naltrexone are not suitable, or disulfiram is preferred and the patient understands the relative risks of taking the drug. The guideline provides details about the necessary evaluation required before prescribing these drugs and the monitoring required.

Comorbid conditions and complications of alcohol misuse
Comorbid mental health disorders commonly include depression, anxiety disorders, and drug misuse. Physical comorbidities are common, including gastrointestinal disorders (in particular liver disease) and neurological and cardiovascular disease. In some people these comorbidities may remit on stopping or reducing alcohol consumption, but many experience long-term consequences of alcohol misuse. For people with comorbid depression or anxiety disorders, the alcohol misuse should be treated first. Depression or anxiety persisting after several weeks’ abstinence should be assessed and treated. People with significant comorbid mental health disorder, and those at high risk of suicide, should be referred to a psychiatrist to make sure that effective assessment, treatment, and risk-management plans are in place.

Thiamine should be given to people at high risk of developing, or with suspected, Wernicke’s encephalopathy. Doses should be toward the upper end of the British National Formulary range. Oral thiamine should be given to harmful or dependent drinkers who are malnourished or at risk of malnourishment, have decompensated liver disease, are in acute withdrawal, or before and during a planned medically-assisted alcohol withdrawal.